Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label maintenance study of NEXIUM in Japanese paediatric patients with reflux esophagitis or NSAID/low-dose aspirin-associated ulcer recurrence risk
2018-000213-20Phase 3
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esomeprazole in erosive esophagitis (EE), gastric ulcer and duodenal ulcer (2 arms), sponsored by AstraZeneca.
02
Drugs
esomeprazole
03
Conditions
erosive esophagitis (EE)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on 2018-000213-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000213-20.